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BEHAVIOURAL EFFECTS OF IV MCPP IN 
SCHIZOPHRENIA 
Sally Szymanski*, David Mayerhoff, Amy Koreen, 
Carmen Lemus, Jose Alvir, Anthony Loebel, Raphael 
Munne, Daniel Umbricht, Steven Sobel, Jeffrey Liebetman 
Hillside Hospital, Psychiatry Research, P.O. Box 38, Glen Oaks, 
NY 11004, USA 
The effect of the serotonergic system on psychotic behaviour 
and sehizophrenia has been recently studied. Meta-chloro- 
phenylpiperazine (MCPP) is a direct-acting 5HT receptor agonist 
which has been shown to have both neurochemical and behav- 
ioural effects in schizophrenic subjects. In this study, we report 
the behavioural effect of I.V. MCPP administration in a cohort 
of new-onset and chronic schizophrenics. 
clozapine trial. Patients were rated for the presence of psycho- 
pathological and tardive dyskinesia at regular intervals. Plasma 
and cerebrospinal fluid homovanillic acid (pHVA, CSF HVA) and 
cerebrospinal 5hydroxyindoleacetic acid (CSF SHIAA) levels were 
collected at baseline and treatment week 3. 
Data from 19 DSM III schizophrenic and schizoaffective dis- 
order patients were examined. The sample was 68% male, 88% 
treatment refractory, 53% had tardive dyskinesia and the mean age 
was 29.5k6.3 years. Dividing the sample into clozapine respond- 
ers vs nonresponders showed that the responders had both a lower 
baseline CSF HVA levels (pc.08) and a CSF HVA/SHIAA ratio 
(pi.04). Plasma HVA levels were not associated with CSF HVA 
values but with CSF SHIAA levels. 
Seventeen drug free schizophrenic subjects (RDC), (47% new- 
onset) received intravenous (0.1 mg/kg) MCPP and evaluated be- 
havioural response at pre and post infusion. An increase in 
agitation, bizarre behaviour, anxiety, thought disorder, with no 
significant change in depression, irritability, grandiosity, distrust- 
fulness, impaired understandability or in overall severity of delu- 
sions or hallucinations was observed. Multiple side effects of 
MCPP were seen with the sensation of warmth and chills being 
the most common. 
Although all increase in psychotic symptoms has been reported 
in schizophrenic patients following an MCPP infusion, in this 
sample, no change in psychotic symptoms, other than thought 
disorder, was noted. An increase in agitation was reported which 
may in part be due to increased motoric restlessness secondary 
to anxiety. The results suggest that MCPP may produce its be- 
havioural responses in schizophrenia patients through nonspecific 
effects on psychopathology as well as through reactions to 
side effects. These and other findings will be presented and 
discussed. 
These results suggest that the dopamine-serotonin relationship 
is important in determining response to clozapine. These and 
other findings will be presented and discussed. 
CHOLINERGIC MECHANISMS IN 
SCHIZOPHRENIA: RELATIONSHIP TO 
SLEEP-EEG ABNORMALITIES AND POSITIVE/ 
NEGATIVE SYMPTOMS 
Rajiv Tandon*, James E. Shipley, JoAnn Goodson, John 
F. Greden 
University of Michigan Schizophrenia Program, Ann Arbor, MI 
48109-0120. USA 
Considerable evidence suggests that ACh mechanisms may play 
a significant role in schizophrenic pathophysiology. Based on 
various data (Tandon and Greden. Arch Gen Psychiatry, 1989, 46: 
745-753). we proposed the following model of dopaminergic 
(DA)/ACh interactions in schizophrenia: (i) disruption of DA/ACh 
balance is important in schizophrenic pathophysiology; (ii) ACh 
activity increases to maintain this balance in the face of increas- 
ing DA activity that occurs in the psychotic phase of the illness; 
(iii) this increased ACh activity exerts a damping effect on the 
production of positive symptoms associated with DA hyperactiv- 
ity; and (iv) this compensatory increase in ACh activity is, in turn, 
accompanied by an increase in nonenduring negative symptoms. 
To test predictions of this model, we studied the effects of 
biperiden (a relatively selective M- 1 anticholinergic agent) on 
positive/negative symptoms and polysomnographic measures in 
drug-free schizophrenic patients. Employing a double-blind, 
placebo-crossover design, we observed that biperiden (in compari- 
son to glycopyrrolate) increased positive symptoms and decreased 
negative symptoms in drug-free schizophrenic patients. At base- 
line, schizophrenic patients showed impaired sleep continuity, and 
shortened REM latency in comparison to normal controls. 
Biperiden increased REM latency in a dose-dependent manner in 
both groups; it decreased REM density to a significantly greater 
extent in the schizophrenic group. These findings are consistent 
with the hypothesized concomitant increases in DA and ACh 
activity in schizophrenia. Our findings further implicate 
the cholinergic system in schizophrenic pathophysiology and sug- 
gest a role for dopaminergic/ACh interactions at least in the 
THE DOPAMINE-SEROTONIN RELATIONSHIP 
IN CLOZAPINE RESPONSE 
Sally Szymanski*, Simcha Pollack, Tom Cooper, Allan 
Safferman, Raphael Munne, Daniel Umbricht, Jeffrey 
Lieberman, Michael Kronig 
Hillside Hospital, Psychiatry Research, P.O. Box 38, Glen Oaks, 
NY 11004, USA 
Clozapine’s atypical antipsychotic properties, e.g. superior ef- 
ficacy, fewer extrapyramidal effects, and a reduced likelihood of 
producing tardive dyskinesia, have been reported. A stronger abil- 
ity to block serotonin vs dopamine receptors has been proposed 
as the underlying mechanism of drug action. Consequently, the 
purpose of this study was to determine the effect of clozapine both 
dopamine and serotonin indices. 
Nineteen treatment refractory and intolerant schizophrenic and 
schizoaffective disorder patients underwent a six week open 
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production of sleep abnormalities and expression of positive and 
negative symptoms. These data indicate the need for systematic 
trials of cholinergic and anticholinergic agents in the treatment of 
positive and negative symptoms of schizophrenia, respectively. 
COVARIANCE OF POSITIVE AND NEGATIVE 
SYMPTOMS DURING TREATMENT WITH 
TYPICAL NEUROLEPTICS AND CLOZAPINE 
Rajiv Tandon,* Saulo CM Ribeiro, Melinda Perez, John 
F. Greden 
University of Michigan Schizophrenia Program, Ann Arbor, MI 
48109-0120. USA 
Although poor response to neuroleptics has traditionally been 
considered a characteristic feature of negative schizophrenic 
symptoms, several recent studies have documented significant im- 
provement in negative symptoms in schizophrenic patients treated 
with neuroleptics. The question of whether neuroleptic-induced im- 
provement in negative symptoms is linked to concomitant im- 
provement in positive symptoms or occurs independently of such 
improvement is unresolved; it is also unclear if this profile is simi- 
lar during treatment with clozapine and typical neuroleptics. To 
address these issues, we studied 120 RDC/DSM-III-R schizo- 
phrenic inpatients at drug-free baseline and after 3-4 weeks of 
treatment with clinically-determined doses of typical neuroleptics. 
We also studied 40 RDUDSM-III-R schizophrenic patients before 
a trial of clozapine and after 4-6 weeks of initiating clozapine 
treatment. Positive and negative symptoms were assessed by the 
BPRS “THOT” factor and the SANS sum of global scores, re- 
spectively. During treatment with typical neuroleptics, there was 
significant improvement in both positive symptoms (15.6k2.9 to 
10.2k3.2) and negative symptoms (12.5k4.2 to 8.6k3.4); the 
change in positive symptoms was highly correlated to the change 
in negative symptoms (~0.60; p<O.OOl). During treatment with 
clozapine, both positive symptoms (from 16.of 3.6 to 12.4f3.5) 
and negative symptoms (from 13.8f4.5 to 10.5f4.1) improved 
significantly; change in positive symptoms was again significantly 
correlated to change in negative symptoms (1=0.63; p<O.Ol). Al- 
though there are sample differences between the two groups mak- 
ing comparisons difficult, these data indicate that negative 
symptoms improve along with positive symptoms in the course 
of initial neuroleptic treatment, both with typical neuroleptics and 
clozapine. Clozapine’s apparent greater efficacy on negative 
symptoms may bc related to its greater efficacy on positive symp- 
toms (in otherwise treatment-refractory patients) and its lower pro- 
pensity to cause EPS. 
A HIGH CONCENTRATION OF PLASMA 
INTERLEUKIN-6 IN SCHIZOPHRENIC 
PATIENTS TREATED WITH NEUROLEPTIC 
DRUGS 
J. Wei*, H-M. Xu, G.P. Hemmings 
Institute of Biological Psychiatry, SAGB, Bangor, Gwynedd LL.57 
2UW. UK 
In a previous study, we found a low concentration of plasma 
interleukin (IL)-la in neuroleptic-free patients with schizophrenia. 
In view of the considerable overlap in the cellular sources and 
biological activity of IL-l, IL-6 and tumor necrosis factor (TNF), 
it was thought necessary to examine all three of the relevant 
cytokines in schizophrenic patients. This study denonstrated that 
the concentration of plasma IL-6 was significantly higher in the 
patients taking neuroleptic drugs (5.95k1.20 pmol/L, n=32) than 
in those not taking neuroleptic drugs(4.8lU.13 pmol/L, n=13, 
p<O.Ol), but was not significantly higher than in normal control 
subjects (5.04+1.78 pmol/L, n=9, p>O.O5). Kruskal-Wallis analy- 
sis of’ variance revealed a significant difference in the concen- 
tration of plasma IL-6 among the patients taking neuroleptic drugs, 
those not taking neurolpetic drugs and normal control subjects 
(H=7.1, df=2, p<O.O5). The increased plasma IL-6 was not 
related to the clinical state of the patients taking neuroleptic drugs. 
No significant differences of plasma IL-ID and TNF-a were found 
between the three groups. These results suggest that neuroleptic 
treatment may increase only IL-6 production, and that the low 
concentration of plasma IL-a found in our previous study may 
be peculiar to schizophrenia. 
CLINICAL REVIEW OF CLOZAPINE 
TREATMENT IN A STATE HOSPITAL 
W. H. Wilson* 
Department of Psychiatry, Oregon Health Sciences University, 
Portland, OR 97201-3098, USA 
We recently reported on a review of the medical records of the 
first 37 patients to begin clozapine treatment at a state hospital 
in Oregon. Records were reviewed for the six months before 
clozapine treatment and six months after. Patients had a long his- 
tory of schizophrenia and had responded poorly to antipsychotic 
medication. Clozapine treatment was generally well tolerated, al- 
though the rate of seizures (8%) was slightly higher than expected. 
Psychotic symptoms decreased as measured by the Brief Psychi- 
atric Rating Scale, as did symptoms of tardive dyskinesia, as 
measured by the Abnormal Involuntary Movement Scale. Thirty- 
four patients remained hospitalized after six months of treatment. 
However, indicators of social function (hospital privilege level, 
community passes, violent episodes, and episodes of seclusion and 
restraint) all showed that patients improved markedly after receiv- 
ing clozapine. We will present data extending this analysis to in- 
clude a six month follow-up of 100 patients, with 68 of the 
patients followed for eighteen months. 
